Literature DB >> 24014569

Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman.

E E Fließer1, P Korsten, M J Koziolek, T B Niewold, D Patschan, G A Müller, S A Patschan.   

Abstract

We report the case of a 19-year-old woman with progressive proliferative lupus nephritis (LN) class III after induction and maintenance therapy with mycophenolate mofetil (MMF). Despite a satisfying clinical improvement proteinuria progressed under this medication. We treated the patient with additional belimumab after discussing other options. Following treatment with belimumab, proteinuria rapidly improved to almost normal levels and clinical remission lasted. Belimumab might hold promise for this indication.

Entities:  

Keywords:  Proliferative lupus nephritis; belimumab; mycophenolate mofetil; systemic lupus erythematosus

Mesh：

Substances：

Year:  2013        PMID： 24014569     DOI： 10.1177/0961203313504145

Source DB:  PubMed          Journal:  Lupus        ISSN： 0961-2033            Impact factor:   2.911


  7 in total

Review 1.  B Cell-Based Treatments in SLE: Past Experience and Current Directions.

Authors:  Stamatis-Nick C Liossis; Chrysanthi Staveri
Journal:  Curr Rheumatol Rep       Date:  2017-11-04       Impact factor: 4.592

2.  Case report: successful treatment of membranous lupus nephritis with belimumab in an African female immigrant.

Authors:  Marie-Angélique De Scheerder; O Boey; E Mahieu; J Vanuytsel; Anne-Marie Bogaert
Journal:  Clin Rheumatol       Date:  2015-12-28       Impact factor: 2.980

Review 3.  Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review.

Authors:  Domenico Paolo Emanuele Margiotta; Fabio Basta; Veronica Batani; Antonella Afeltra
Journal:  BMC Nephrol       Date:  2018-03-07       Impact factor: 2.388

Review 4.  Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.

Authors:  Marlene Plüß; Silvia Piantoni; Björn Tampe; Alfred H J Kim; Peter Korsten
Journal:  Hum Vaccin Immunother       Date:  2022-05-19       Impact factor: 4.526

5.  Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus.

Authors:  Marlene Plüß; Björn Tampe; Noah Niebusch; Michael Zeisberg; Gerhard A Müller; Peter Korsten
Journal:  Front Med (Lausanne)       Date:  2020-05-27

6.  Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report.

Authors:  Francesco Fontana; Gaetano Alfano; Marco Leonelli; Caterina Cerami; Giulia Ligabue; Amelia Spinella; Giorgia Citriniti; Carlo Umberto Manzini; Clodoveo Ferri; Gianni Cappelli
Journal:  BMC Nephrol       Date:  2018-10-20       Impact factor: 2.388

7.  Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies.

Authors:  Luca Petricca; Maria Rita Gigante; Annamaria Paglionico; Stefano Costanzi; Gisella Vischini; Clara Di Mario; Valentina Varriano; Giacomo Tanti; Barbara Tolusso; Stefano Alivernini; Giuseppe Grandaliano; Gianfranco Ferraccioli; Elisa Gremese
Journal:  Front Med (Lausanne)       Date:  2020-10-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.